Musculoskeletal Syndrome of Menopause: HRT Guide

Key Takeaways: A 2024 review formally named musculoskeletal syndrome of menopause as a unified clinical entity covering joint pain, muscle loss, accelerated bone loss, osteoarthritis progression, and connective tissue changes. More than 70% of women experience symptoms; 25% are disabled by them. The syndrome is driven by simultaneous estrogen and testosterone decline, both of which act on receptors throughout muscle, tendon, cartilage, and bone. Randomized data on hormone therapy for joint pain shows modest but consistent benefit, with the strongest effect on preventing new symptoms when HRT is started within 10 years of menopause. Progressive resistance training is the essential non-hormonal pillar. The combined approach -- HRT (estrogen plus testosterone where appropriate), resistance training, adequate protein, and metabolic optimization -- is the most complete framework available in 2026.

A Real Syndrome, Finally Named

For decades, women in their late forties and early fifties have told doctors the same story: joints that suddenly hurt, muscles that will not respond to training, tendons that flare for no reason, mornings that start with stiffness that was not there a year ago. The complaints were often dismissed as aging, deconditioning, or somatization.

In 2024, a clinical review in the journal Climacteric gave this pattern its proper name: musculoskeletal syndrome of menopause [1]. The point of naming it was not academic. It was a recognition that the joint pain, muscle loss, tendinopathy, and bone fragility that cluster around the menopausal transition share a hormonal driver and should be treated as connected manifestations of a single underlying change, not as separate problems to manage in isolation.

This article walks through what the syndrome is, what the evidence says about hormone therapy as part of the treatment, and how women navigating midlife musculoskeletal symptoms can put together a comprehensive plan.

What the Syndrome Includes

Musculoskeletal syndrome of menopause encompasses several overlapping clinical features. Not every woman has all of them, but most women have several:

Arthralgia (Joint Pain)

The most common symptom. Surveys consistently show that 50 to 60% of women in perimenopause and early postmenopause report new or worsening joint pain [1] [2]. The pattern is typically symmetric, affects multiple joints (hands, knees, hips, shoulders), and often features morning stiffness lasting less than an hour. It is not inflammatory arthritis -- joint swelling and laboratory inflammation markers are typically normal -- but the pain is real, and it tracks with the hormonal transition.

Sarcopenia (Muscle Loss)

Muscle mass declines at roughly 0.5 to 1% per year through midlife, with the rate of loss accelerating during the menopausal transition. Strength declines even faster than mass, particularly fast-twitch fibers. The functional consequences -- reduced grip strength, slower walking speed, harder recovery from minor strains -- compound over time and increase the risk of falls and disability.

Osteoporosis and Accelerated Bone Loss

Bone mineral density falls fastest in the first five to seven years after the final menstrual period -- the so-called "transmenopausal bone loss" window. Women can lose up to 20% of their bone mass during this period. Fracture risk rises in parallel. For a deeper dive on bone-specific hormonal effects, see HRT and Bone Density in Women.

Osteoarthritis Progression

Cartilage maintenance depends partly on estrogen. Women's osteoarthritis rates rise sharply at menopause and exceed men's by midlife. Hand osteoarthritis in particular has a strong menopausal pattern, with the typical "knobby finger joint" presentation often beginning in the first few years after the final period.

Tendinopathy and Connective Tissue Disorders

Tendons, ligaments, and joint capsules are estrogen-responsive. The menopausal transition is associated with a sharp rise in conditions like rotator cuff tendinopathy, lateral epicondylitis (tennis elbow), plantar fasciitis, and adhesive capsulitis (frozen shoulder). For the frozen shoulder pattern specifically, see HRT and Frozen Shoulder in Menopause.

Disability Burden

Surveys show that approximately 25% of women with musculoskeletal syndrome of menopause are disabled by their symptoms at some point during the transition [1]. This is not a minor quality-of-life issue. It is a major driver of reduced work capacity, reduced exercise capacity, and the cascade of metabolic problems that follows when previously active women become less active.

Why Hormones Matter for the Musculoskeletal System

The biological case for hormonal involvement is strong. Estrogen and androgen receptors are present throughout muscle, tendon, ligament, cartilage, synovium, and bone -- the entire musculoskeletal system is hormone-responsive.

Estrogen's Role

Estrogen has multiple direct effects on the musculoskeletal system:

• Anti-inflammatory action on joint tissues. Estrogen suppresses pro-inflammatory cytokines including IL-6, TNF-alpha, and IL-1 beta that drive arthralgia and accelerate cartilage breakdown.
• Cartilage maintenance. Chondrocytes express estrogen receptors; estrogen supports cartilage matrix production and slows the degradative cascade that defines osteoarthritis.
• Bone remodeling balance. Estrogen restrains osteoclast activity. When estrogen falls, osteoclasts outpace osteoblasts and net bone loss accelerates.
• Tendon and ligament integrity. Estrogen supports collagen synthesis and modulates the type I to type III collagen ratio that determines tensile strength. When estrogen drops, collagen quality and quantity decline.
• Muscle protein synthesis. Estrogen has modest but real anabolic effects on muscle, particularly when combined with mechanical loading.

When estrogen falls sharply at menopause, all of these protective effects weaken simultaneously. This is why the syndrome presents as a cluster rather than as one isolated symptom.

Testosterone's Role

Testosterone is the dominant anabolic hormone for muscle mass and strength in both sexes. Women have roughly one-tenth the testosterone levels of men, but the hormone is still essential. Women's free testosterone declines steadily from the late twenties onward -- the menopausal transition does not cause a sharp drop in testosterone the way it does for estrogen, but the cumulative decline by the fifties is substantial [3].

Testosterone effects on the musculoskeletal system include:

• Muscle protein synthesis. Androgen receptors on muscle fibers respond to even modest testosterone elevations with increased synthesis.
• Strength and power output. Independent of mass, testosterone supports neuromuscular function and force generation.
• Bone formation. Testosterone contributes directly to osteoblast activity, and indirectly via aromatization to estrogen within bone tissue.
• Tendon and connective tissue maintenance. Androgen receptors are present in tendon fibroblasts and contribute to collagen turnover.

For women in midlife with prominent muscle loss, weakness, and slow recovery, testosterone is often the missing piece in an estrogen-only HRT regimen. For the broader picture on testosterone and muscle in women, see Testosterone for Joint Pain and Muscle Loss in Women.

What the Evidence Says About HRT

Joint Pain (Arthralgia)

The Women's Health Initiative remains the largest randomized trial that looked at joint pain as an outcome. In the WHI estrogen-alone trial, women on conjugated equine estrogen reported significantly less joint pain at one year compared with placebo, with effect sizes in the small-to-moderate range. The estrogen-plus-progestin trial showed similar but smaller effects [4].

A more recent systematic review and meta-analysis published in 2025 [2] pooled 17 trials of hormone therapy for musculoskeletal pain in menopausal women. Key conclusions:

• Hormone therapy produced modest improvement in joint pain versus placebo, with effect sizes that did not reach the threshold for "large" benefit but were consistent across studies
• The clearest signal was in prevention of new musculoskeletal symptoms rather than reversal of established pain
• The pooled effect on generalized musculoskeletal pain across all studies was non-significant, but the trial-level heterogeneity was high

The mixed picture reflects a real clinical reality: not all musculoskeletal pain in midlife is hormonally driven, and not all hormonally driven pain responds quickly or completely to HRT. But for the substantial subset of women whose pain tracks with the transition, HRT is one of the more effective tools available.

Muscle Mass and Strength

Trials of estrogen alone show small effects on muscle mass and strength. Trials adding testosterone -- typically using transdermal testosterone at female physiologic doses -- show more substantial gains in lean mass and strength, particularly when combined with progressive resistance training [3] [5].

The combined picture: estrogen helps prevent further muscle loss; testosterone helps rebuild what has been lost. For women in the earlier phases of the transition with mild symptoms, estrogen alone may be sufficient. For women with established sarcopenia, weakness, or slow recovery, the addition of low-dose transdermal testosterone produces a more complete response.

Bone Density and Fractures

This is where the evidence is strongest. HRT prevents postmenopausal bone loss, reduces fracture incidence (including hip and vertebral fractures), and is more effective than most non-hormonal alternatives when started in the early postmenopausal window. The WHI showed approximately 33% reduction in hip fractures with estrogen plus progestin. For a deeper look at the bone-specific evidence and clinical pathways, see HRT and Bone Density.

Osteoarthritis

The data on HRT and osteoarthritis progression is more limited. Observational studies suggest HRT may slow knee osteoarthritis progression in women started early in menopause, but randomized data are sparse and inconsistent. The 2025 evidence base does not support HRT as a primary osteoarthritis treatment, but it supports the broader argument that hormonal status is part of the disease.

Connective Tissue and Tendinopathy

Most evidence here comes from observational studies and mechanism research rather than randomized trials. The accumulated picture is that estrogen supports connective tissue health and that HRT-treated women have lower rates of several tendinopathies and frozen shoulder. The randomized trial evidence is thin but generally consistent with the mechanistic story.

The Timing Window Matters

The single most important factor that determines whether HRT produces musculoskeletal benefit is when in the menopausal transition it is started.

Women who start HRT within roughly 10 years of menopause (or before age 60) get the maximum benefit on bones, joints, connective tissue, and broader health outcomes. Women who start more than a decade after menopause get less musculoskeletal benefit and more cardiovascular risk. For a full discussion of the timing window, see When to Start HRT: The Timing Hypothesis.

This timing dependency reflects the fact that estrogen withdrawal triggers a wave of inflammatory, fibrotic, and degenerative changes that are easier to prevent than to reverse. The earlier you intervene -- ideally during late perimenopause or the first few years after the final period -- the more of the syndrome you prevent.

For women already past the 10-year window but with severe musculoskeletal symptoms, HRT can still help quality of life. The decision becomes more individualized, with risk-benefit weighed against alternative approaches.

A Practical Treatment Framework

The most effective approach to musculoskeletal syndrome of menopause is layered. Each layer adds value; no single layer is sufficient on its own.

Layer 1: Resistance Training (Non-Negotiable)

Progressive resistance training is the single most evidence-based intervention for preventing menopausal muscle and bone loss. The protocol that works:

• Frequency: 2 to 4 sessions per week
• Intensity: Loads heavy enough that the last 2 to 3 reps of each set are genuinely hard
• Movements: Compound, multi-joint exercises (squat, deadlift or hip hinge pattern, push, pull, carry)
• Progression: Adding weight, reps, or sets over time -- not staying at the same load forever

Women in their forties, fifties, and sixties can build meaningful muscle and strength with appropriate programming. Light cardio and aerobic-style exercise do not produce the same musculoskeletal effects -- the stimulus must be progressive resistance against meaningful load.

Layer 2: Nutrition

• Protein: 1.2 to 1.6 g per kg body weight per day, distributed across meals with at least 25 to 30 g per meal to maximize muscle protein synthesis
• Vitamin D: Sufficient blood levels (typically 30 to 50 ng/mL); supplementation often needed
• Omega-3 fatty acids: Anti-inflammatory effect; 1 to 3 g of combined EPA/DHA daily from fish or supplements
• Calcium: 1,000 to 1,200 mg per day from food, supplements only if dietary intake is inadequate
• Adequate calories: Chronic underfueling accelerates muscle loss and impairs HRT response

Layer 3: Hormone Therapy

For women within the 10-year window after menopause who do not have contraindications, hormone therapy is a reasonable layer to add. The components most relevant to musculoskeletal symptoms:

• Transdermal estradiol (patch, gel, or spray) provides systemic estrogen without first-pass liver effects. The dose is titrated to symptom control, typically starting at 0.025 to 0.05 mg per day for patches.
• Progesterone (oral micronized or transdermal) is required for women with an intact uterus to protect the endometrium. Often given at bedtime because of its sedating effect on sleep.
• Transdermal testosterone at female physiologic doses (typically 0.5 to 5 mg per day depending on formulation) for women with prominent muscle loss, weakness, libido drop, or fatigue. Cream and gel are the most common forms; pellets and weekly subcutaneous injections are also used in some clinics.

The choice of regimen and dose should be individualized based on symptom pattern, contraindications, and risk factors. Comprehensive women's hormone clinics evaluate estrogen, testosterone, thyroid, and metabolic status together rather than treating each in isolation. See Best Online HRT Clinic for Women for clinics that handle the full hormonal workup.

Layer 4: Metabolic Optimization

Insulin resistance accelerates muscle loss, increases inflammation, and worsens joint pain. Women in midlife frequently develop insulin resistance even without overt diabetes. Addressing it -- through diet, exercise, sleep, and where appropriate, medications -- improves the substrate on which HRT acts.

• HbA1c, fasting insulin, and a lipid panel give a useful baseline
• Sleep duration of 7 to 9 hours; sleep disruption worsens insulin sensitivity and muscle recovery
• Stress management; chronic cortisol elevation accelerates muscle loss

Layer 5: Targeted Orthopedic Care

For specific musculoskeletal complaints -- frozen shoulder, tendinopathy, severe knee osteoarthritis -- standard orthopedic interventions remain essential. Physical therapy, image-guided injections, and surgical evaluation where appropriate work alongside the hormonal and lifestyle layers, not instead of them.

When to Suspect the Syndrome

The clinical pattern that should trigger consideration of musculoskeletal syndrome of menopause:

• Age 40 to 60
• New or worsening joint pain, especially symmetric and affecting multiple joints
• Morning stiffness lasting less than an hour
• Unexplained muscle weakness, slower recovery from training, or loss of strength
• Tendon or connective tissue problems that recur or will not heal
• Other menopausal symptoms in parallel: hot flashes, sleep disruption, mood changes, vaginal dryness, irregular cycles
• No clear evidence of inflammatory arthritis on workup (normal CRP, ESR, RF, anti-CCP)

The differential diagnosis still includes inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis), autoimmune disease (lupus, polymyalgia rheumatica), thyroid disease, vitamin D deficiency, and statin-related myalgia. A standard workup rules these in or out. But for the large group of midlife women whose musculoskeletal symptoms cluster with the menopausal transition and whose workups are unremarkable, hormonal contribution is the most likely explanation.

Limitations of the Hormonal Story

A few important caveats:

• Not all musculoskeletal pain in midlife is hormonal. Aging, mechanical wear, prior injury, and lifestyle all contribute. HRT is one tool, not a universal cure.
• The randomized evidence is modest. HRT improves joint pain in trials, but the effect size is small to moderate, not transformative for every woman.
• Individual response varies. Some women experience dramatic relief on HRT; others see only partial improvement. Trial-and-error with regimen and dose is normal.
• Resistance training is irreplaceable. No hormonal intervention substitutes for the mechanical loading stimulus. Women who rely on HRT alone without exercising do not get the full musculoskeletal benefit.
• Contraindications matter. Personal or family history of breast cancer, active liver disease, thromboembolic history, and other conditions limit who can safely use systemic HRT.

The framework here is meant to help women and clinicians think about midlife musculoskeletal symptoms as a connected hormonal pattern rather than a set of unrelated orthopedic complaints. Whether and how to use HRT remains an individualized decision.

What This Means in 2026

The recognition that 70% of menopausal women experience musculoskeletal symptoms, and that 25% are disabled by them, has shifted clinical thinking in several ways:

1. Hormonal status now belongs in the workup for midlife joint pain that does not fit a clear orthopedic or autoimmune pattern
2. Combined hormone therapy (estrogen plus testosterone where appropriate) is increasingly the preferred approach for women with prominent muscle and connective tissue symptoms, not just vasomotor complaints
3. Multidisciplinary care -- gynecology, endocrinology, orthopedics, physical therapy, and primary care -- works better than single-organ referral

For women in midlife navigating new musculoskeletal symptoms, the practical path is to find a clinician who understands the syndrome rather than treating each symptom as a separate problem. Comprehensive women's hormone clinics evaluate the full hormonal, metabolic, and musculoskeletal picture together. See the Best Online HRT Clinic for Women comparison for clinics that handle this kind of integrated evaluation.

Related Reading

• Testosterone for Joint Pain in Women -- the testosterone-specific evidence
• HRT and Bone Density in Women -- the bone component of the syndrome
• HRT and Frozen Shoulder in Menopause -- the connective tissue component
• When to Start HRT: The Timing Hypothesis -- why timing matters so much
• Perimenopause Symptoms Timeline -- where musculoskeletal symptoms fit in the broader transition
• Best Online HRT Clinics for Women -- comprehensive hormonal evaluation

References

1. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466-472. PMID: 39077777

2. Overton R, Amini P, Chew A, et al. The effect of hormone replacement therapy on musculoskeletal pain in menopausal women: A systematic review and meta-analysis. Post Reproductive Health. 2025. DOI: 10.1177/20533691251403087

3. Davis SR, Wahlin-Jacobsen S. Testosterone in women--the clinical significance. Lancet Diabetes Endocrinol. 2015;3(12):980-992. PMID: 26358173

4. Chlebowski RT, Cirillo DJ, Eaton CB, et al. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause. 2013;20(6):600-608. PMID: 23511707

5. Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31474158

6. Wright VJ, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric full text. 2024. Taylor & Francis